Drug Approval | June 16, 2023
Briefs: Natco Pharma and Panacea Biotec
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
Panacea Biotec has announced the launch of its new range of high-quality pediatric food & nutritional products
The company has now received the Establishment Inspection Report (EIR) indicating closure of the inspection
The randomised, multi-centre, evaluator blinded, parallel group, active controlled Phase 3 trial is being led by Lanhzou Biotechnique Development
The new API plant is set up to meet all domestic and international regulatory standards and will manufacture niche molecules that have a global requirement
Agreement provides customers in the majority of Europe* access to supply through Univar Solutions distribution network
Acquisition accelerates Cosette’s women’s health portfolio; with a differentiated, commercial stage, patent protected product
Lantern is receiving an exclusive and worldwide option to license intellectual property from Bielefeld University related to the collaboration and IP generated from the collaboration
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Establishes distribution center in top hub for international shipping
Sun Pharma will have exclusive rights to commercialise Nidlegy for indications of skin cancers in the territories of Europe, Australia and New Zealand. Philogen will complete pivotal clinical trials for the product in Europe
Subscribe To Our Newsletter & Stay Updated
